Litcius/Paper detail

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Karim Fizazi, Charles G. Drake, Tomasz M. Beer, Eugene D. Kwon, Howard I. Scher, Winald R. Gerritsen, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Riccardo Danielli, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, M. Brent McHenry, Allen Chen, Christopher J. Logothetis

2020European Urology175 citationsDOIOpen Access PDF

Topics & Concepts

MedicineProstate cancerIpilimumabPlaceboRadiation therapyProstatectomyOncologyInternal medicineClinical trialCancerUrologyImmunotherapyPathologyAlternative medicineProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors | Litcius